The Interaction of Gabapentin and N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) on Mechanical Allodynia in Rats with a Spinal Nerve Ligation by Park, Jong Yeon & Jun, In Gu
INTRODUCTION
Peripheral nerve injury may result in mechanical allody-
nia, a condition of extreme cutaneous sensitivity to normal-
ly innocuous mechanical stimuli. Unilateral ligation of L5
and L6 spinal nerves produces some signs that seem repre-
sentative of neuropathic pain (1). Signs of mechanical allo-
dynia were most evident in the nerve ligation model among
several experimental animal models (2). The spinal pharma-
cology at spinal nerve ligation-induced allodynia has been
shown to be distinct from that associated with acute noci-
ceptive input.
Adenosine is an endogenous purine compound function-
ing as an extracellular signaling molecule in the central and
peripheral nervous systems (3). Adenosine is released locally
at tissue sites in response to trauma, ischemia and interac-
tions with specific receptors. There are many experimental
data showing the role of adenosine in the modulation of
nociceptive transmission at the spinal level (4, 5). Four types
of adenosine receptors have been identified and cloned as
A1, A2A, A2B, and A3 (3, 6). It is known that the antiallodyn-
ic effects are mediated through the activation of spinal A1
adenosine receptors and motor dysfunction effects are medi-
ated through A2 adenosine receptors at the spinal level (7).
Gabapentin is a 3-alkylated analogue of gamma-amino
butyric acid, which modulates α 2δcalcium-channel sub-
units, a mechanism thought to be important in neuropathic
pain (8). Gabapentin analgesia is unaffected by opioid antag-
onism, and repeated administration of gabapentin does not
lead to analgesic tolerance (9). Preclinical studies suggest
that additive interactions may occur between gabapentin
and morphine (10, 11) and that opioid tolerance can be pre-
vented by the use of gabapentin (12). However, mechanisms
underlying analgesic effects of gabapentin are not fully under-
stood.
The combination of mechanistically distinct analgesic
agents may result in additivity or synergism and may improve
efficacy at lower doses, with fewer side effects than with the
use of one agent alone. This strategy has been advocated in
cases of partial treatment response (13).
There is no study on the antiallodynic interaction of intra-
thecal gabapentin and A1 adenosine receptor agonist in the
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The Interaction of Gabapentin and N
6-(2-phenylisopropyl)-adenosine
R-(-)isomer (R-PIA) on Mechanical Allodynia in Rats with a Spinal
Nerve Ligation
We examined the antiallodynic interaction between gabapentin and adenosine A1
receptor agonist, N
6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA), in a rat
model of nerve ligation injury. Rats were prepared with ligation of left L5-6 spinal
nerves and intrathecal catheter implantation for drug administration. Mechanical
allodynia was measured by applying von Frey filaments. Gabapentin and R-PIA
were administered to obtain the dose-response curve and the 50% effective dose
(ED50). Fractions of ED50s were administered concurrently to establish the ED50 of
the drug combination. The drug interaction between gabapentin and R-PIA was
analyzed using the isobolographic method. Adenosine A1 receptor antagonist was
administered intrathecally to examine the reversal of the antiallodynic effect. Loco-
motor function changes were evaluated by rotarod testing. Intrathecal gabapentin
and R-PIA and their combination produced a dose-dependent antagonism against
mechanical allodynia without severe side effects. Intrathecal gabapentin synergis-
tically enhanced the antiallodynic effect of R-PIA when coadministered. There were
no significant changes in rotarod performance time, except gabapentin 300 μ g. In
the combination group, the maximal antiallodynic effect was reversed by A1 adeno-
sine receptor antagonist. These results suggest that activation of adenosine A1
receptors at the spinal level is required for the synergistic interaction on the mechani-
cal allodynia.
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spinal nerve ligation rat model. Therefore, in the present
study, we have investigated the intrathecal interaction of
gabapentin and A1 adenosine receptor agonist, R-PIA (N6-
[2-phenylisopropyl]-adenosine R-[-]isomer) on mechanical
allodynia in nerve-ligated neuropathic pain rats. The effect
of A1 adenosine receptor antagonist (DPCPX; 1,3-Dipropyl-
8-cyclopentylxanthine) against the antiallodynic effect pro-
duced by combination of each drug was also examined.
MATERIALS AND METHODS
This study was performed under a protocol approved by
the Animal Use and Care Committee at ASAN Institute for
Life Science. The experiments were conducted in male Sp-
rague-Dawley rats (weight 160-180 g), which were housed
individually in a temperature-controlled vivarium and allow-
ed to acclimate for 3 days in a 12/12-hr, light/dark cycle.
For creating the neuropathic rat model, a surgical procedure
was performed (1). Under enflurane anesthesia, the left L5
and L6 spinal nerves were gently isolated and ligated tight-
ly with 6-0 black silk distal to the dorsal root ganglion and
proximal to the formation of the sciatic nerve. If the rats
showed a withdrawal threshold of <4.0 g by postoperative
day 7, these rats were defined as demonstrating mechanical
allodynia. For spinal drug administration, the rats were chron-
ically implanted with catheters as previously described (14).
Intrathecal polyethylene catheter (PE-10, Becton Dickinson
and Company, Sparks, MD, U.S.A.) was passed caudally from
the cistern magna to the spinal cord level of lumbar enlarge-
ment. Proper location was confirmed by a temporary motor
block of both hindlimbs after injection of 2% lidocaine 10
μ L. Only animals with no evidence of neurologic deficit after
the operation were studied. Mechanical allodynia develops
within 1 week after nerve ligation surgery and it lasts for 6-
8 weeks. All experiments were conducted 1 week after implan-
tation of the intrathecal catheter. The animals were 8-10
weeks of age at the time of drug testing.
For intrathecal administration, the drugs were given by
using a microinjection syringe over a 60-sec interval in a vol-
ume of 10 μ L, followed by a 10 μ L flush. The drugs given
were blind to the experimenter. For the determination of
the time to peak effect and the dose (ED50) estimated to pro-
duce 50% maximal possible effect (%MPE) for each drug,
gabapentin (Sigma, St. Louis, MO, U.S.A.) and R-PIA (Sigma)
were administered intrathecally. The doses of 3, 10, 30, 100,
and 300 μ g (n=9 per subgroup) were injected for gabapentin,
and 0.03, 0.1, 0.3, 1, 3, and 10 μ g (n=9 per subgroup) were
injected for R-PIA, respectively. Fractions of ED50s (1/2, 1/4,
1/8, and 1/16; n=9 per subgroup) were administered intrathe-
cally in an equal dose ratio to establish the ED50 of the drug
combination. When the drug combinations were given, the
intrathecal injections were concurrent because the times of
the peak effect of intrathecal gabapentin and R-PIA coin-
cided. Thereafter, the interaction between these two drugs
was assessed isobolographically. For the evaluation of an antag-
onistic effect in each pretreatment group, DPCPX (Sigma)
10 μ g (n=9) was administered intrathecally 15 min before
injections of the combination of the two. For the control
group, normal saline (n=9) was administered. The maximal
reversal from the peak effect of the combination group for
antagonist was assessed and compared with peak %MPE.
All drugs were dissolved in 0.9% sodium chloride solu-
tion. There was at least a 7-day interval between drug injec-
tions of successive experiments to minimize any possibility
of tolerance development and to eliminate the residual effects
of a drug. Each animal received a maximum of three injec-
tions.
Behavioral testing was performed during the day portion
of the circadian rhythm. All behavioral tests were conduct-
ed at fixed times (10:00 am-1:00 pm) in a quiet room by
the same person who was kept unapprised of both the inject-
ed solution and the dose used. To undertake these measure-
ments of a mechanical threshold, the rats were placed in an
individual plastic cage with a wire mesh bottom. After 20
min, mechanical threshold was measured by applying a series
of 8 calibrated von Frey filaments (0.40, 0.70, 1.20, 2.00,
3.63, 5.50, 8.50, and 15.1 g; Stoelting Co., Wood Dale, IL,
U.S.A.) to the midplantar surface of the hindpaw ipsilateral
to the nerve injury until a positive sign for pain behavior was
elicited. It was held for 6 sec. A brisk withdrawal or paw
flinching was considered as positive responses, in which case
the next filament tested was the next lower force. In the
absence of such response, the next filament tested was the
next greater force. In the absence of a response at 15 g of
pressure, the animals were assigned to this cutoff value. The
mechanical stimulus producing a 50% likelihood of with-
drawal was determined by using the up-down method (15).
Measurements were taken before and 15, 30, 45, 60, 90,
120, and 180 min after an intrathecal dose of the drug(s).
Baseline threshold value for each animal at each drug trial
was determined by checking responses to von Frey filaments
on the same day just before drug injection. Locomotor func-
tion changes in the neuropathic rats were evaluated by rotar-
od testing (Acceler rota-rod for rats 7750; Ugo Basile, Com-
erio-Varese, Italy). Neuropathic rats were acclimated to revolv-
ing drums and habituated to handling to ameliorate stress
during testing. Before the actual day of drug testing, rats
were given three training trials on revolving drums having
an axis diameter of 6.0 cm and a corrugated surface for 2
days. Rats were placed on the drum rotating at lowest speed
of 4 rpm and the speed was increased as the rate of 0.12 rpm/
sec, maximally to 40 rpm. Rats able to remain on the revolv-
ing drum for a minimum of 120 sec were selected for drug
testing. The mean of 3 training runs served as a control per-
formance time. Rotarod performance time was measured at
20, 60, 90, 120, and 180 min after intrathecal injection.
Each test was performed three times at 5-min intervals, and680 J.Y. Park and I.G. Jun
the mean values were compared.
We graded the placing and stepping function of the hind
paw as follows: 0, normal brisk placing and stepping reflex
response (normal weight bearing); 1) sluggish response to
dragging the dorsum of hind paw at the edge of table (weak-
ness of the hind paws and poorly coordinated movement of
the hind limbs during ambulation); and 2) no reflex (signif-
icant flaccidity and loss of weight bearing in the hindquarters).
Withdrawal threshold data from von Frey hair testing were
obtained as the actual threshold in grams and were convert-
ed to %MPE using the formula: %MPE for antiallodynia=
([postdrug threshold-baseline threshold]/[15 g-baseline thresh-
old])×100, where postdrug threshold means the largest
threshold observed after intrathecal injection. The cutoff value
was defined as a stimulus intensity of 15 g for the mechani-
cal threshold (i.e., %MPE=100). The peak drug effect was
used to calculate a %MPE, and these data were used to plot
a %MPE versus log dose curve. The ED50 values, slopes, and
95% confidence intervals were calculated using dose-response
data. Variances and its 95% confidence intervals for the the-
oretical ED50 may also be calculated from the variances of each
component administered alone (16). To determine whether
the drug interaction is additive or synergistic, isobolograph-
ic analysis was performed. An isobologram was constructed
by plotting the ED50 value for gabapentin on the x axis and
the ED50 values for R-PIA on the y axis. Individual ED50 val-
ues for each agonist were resolved from the combination dose
required to cause 50% MPE and were plotted on the isobolo-
gram as the experimental combination dose. The theoretical
additive dose of combination was calculated. Experimental
values were compared with theoretical additive values as
defined by the theoretical additive line. The theoretical addi-
tive point lies on a line connecting the ED50 values of the
individual drugs, and experimental values that lie below
and to the left of this additive line were considered to be syn-
ergistic. 
Data were expressed as mean±SEM. The difference bet-
ween the theoretical additive ED50 value and the experimen-
tal ED50 value was compared using a Student’s t-test. The
least antagonistic effect for each pretreatment group was
compared with the peak agonistic effect of the combination
group using the unpaired t-test. A p value <0.05 was con-
sidered to be statistically significant.
RESULTS
After spinal nerve ligation, most rats displayed normal
general behavior and weight gain. After catheter implanta-
tion in the animals with nerve ligation, the thresholds for
evoking hindpaw withdrawal were in the range of 1-4 g for
all rats.
Intrathecal gabapentin, R-PIA, and their combination
resulted in a dose-dependent antiallodynic effect (Fig. 1).
Although not being closely paralleled, the slope of the com-
bination group was shifted to the left side in larger doses
compared with gabapentin (3-300 μ g) and R-PIA (10 μ g),
respectively (Fig. 1). The ED50 values and slopes (95% con-
fidence intervals) were as follows: 10.4 (5.3-20.4) μ g and 39.5
(26.4-52.6) for gabapentin, 0.2 (0.1-0.3) μ g and 35.2 (25.6-
44.7) for R-PIA, and 1.8 μ g (1.4-2.2) and 70.7 (50.2-91.3)
for their combination, respectively. The high slope value of
the combination group could reflect an increased efficacy.
The time-effect courses of these two agonist groups and their
combination groups were similar in general (Fig. 2). The
maximal effects occurred within 15-30 min and then gradu-
ally decreased up to the previous baseline level over time for
all doses of each group. There was a dose-dependent increase
in magnitude and duration of the effect. A somewhat longer
antiallodynic time course was observed in some rats after
the injections of gabapentin 100 or 300 μ g and R-PIA 1, 3
or 10 μ g. Intrathecal normal saline produced only a slight
increase in withdrawal response, which means that vehicles
do not have an effect on the action of each drug and their
combination.
A synergistic effect was found in the gabapentin plus R-
PIA combination group (Fig. 3). The experimentally deter-
mined gabapentin plus R-PIA combination ED50 (±SEM)
was 1.7 (±0.2) μ g for gabapentin and 0.03 (±0.006) μ g
for R-PIA. The theoretical additive ED50 was calculated to
be 5.2 (±1.1) μ g for gabapentin and 0.1 (±0.02) μ g for
R-PIA. The experimental value of the gabapentin plus R-
PIA combination group was significantly smaller than the
calculated theoretical additive value (p<0.05). The standard
errors of these two points on the isobologram show that they
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Fig. 1. Dose-response curves from the peak effects of percent
maximal possible effect (%MPE) for antiallodynia in the gabapen-
tin, N
6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA), and
gabapentin plus R-PIA groups. These curves show a dose-depen-
dent antiallodynic effect. Data are expressed as mean±SEM.
Doses (μ g) are represented logarithmically on the x axis and
peak %MPE is represented on the y axis. Asterisks indicate that
the mean %MPE of each group is significant compared with the
smallest dose. *p<0.05; unpaired t-test. I.T., intrathecal injection.
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do not overlap, which supports a significant synergistic inter-
action.
Pretreatment with DPCPX remarkably attenuated the
maximal antiallodynic effect produced by the intrathecal
gabapentin plus R-PIA combination after 15 min (p<0.05)
(Fig. 4). In the DPCPX pretreatment group, the antiallodyn-
ic effect of both drug combination was significantly reversed
during the entire experiment. DPCPX alone produced only
a slight increase in %MPE (data not shown) and this sug-
gests that DPCPX does not have an effect on antiallodynia.
Some rats showed mild-to-moderate motor weakness or
sedation with the largest dose of each drug, but no severe
motor weakness or sedation was observed in any rats. The
incidence and magnitude of side effects were not consider-
ably increased in the combination group. Moderate motor
weakness was observed in 2 rats (1 in the gabapentin 300 μ g
group and 1 in the R-PIA 10 μ g group). No other adverse
effects were noted. The occurrence of mild-to-moderate motor
weakness returned to the baseline level within 3 hr. The seda-
tive effect also returned to the baseline level within 3 hr.
We observed no significant change in rotarod performance
time at gabapentin (3-100 μ g), R-PIA (0.03-10 μ g), and
gabapentin plus R-PIA combination. However, at a dose of
gabapentin 300 μ g, the locomotor function was significant-
ly decreased from 20 to 60 min after drug administration
(Fig. 5).
DISCUSSION
We found that intrathecal gabapentin, R-PIA and their
combination produced a dose-dependent increase of with-
drawal threshold for a spinally-mediated mechanical allody-
nia. In addition, we observed that gabapentin enhanced the
effect of R-PIA synergistically when coadministered intrathe-
cally.
Saline (n=9)
Fig. 2. Time course of antiallodynic effects by intrathecal injection
of gabapentin (A), N
6-(2-phenylisopropyl)-adenosine R-(-) iso-
mer (R-PIA) (B), and gabapentin plus R-PIA (C). These curves
show a dose-dependent antiallodynic effect in each group. Data
are expressed as mean±SEM. Asterisks indicate that mean per-
cent maximal possible effect (%MPE) of each group for antiallo-
dynia at that time point is significant compared with baseline value.
*p<0.05; one-way repeated-measures analysis of variance fol-
lowed by multiple comparisons (Tukey’s method). I.T., intrathe-
cal injection. 
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It has already been reported that the allodynic response to
mechanical stimuli could be attenuated by intrathecal admin-
istration of R-PIA in a dose-dependent manner, but there
were no significant motor weakness (17, 18). It is confirmed
that such an antiallodynic effect is mediated by the spinal
adenosine A1 receptor subtype with administration of the
selective antagonist (17). Several animal neuropathic pain
models induced by sciatic chronic constriction injury and
intrathecal strychnine suggest an antiallodynic effect medi-
ated by the spinal adenosine A1 receptor (17-19). We also
observed a similar result in this spinal nerve ligation model
after administration of intrathecal R-PIA.
Previous studies demonstrated that both A1 and A2 recep-
tor subtypes are concentrated in a very small area of the dor-
sal horn and are only localized diffusely throughout the ven-
tral horn (20). It is reported that there was no evidence for
up-regulation in spinal A1 receptors after spinal nerve liga-
tion and that spinal cord adenosine was decreased after spinal
nerve ligation (21).
Gabapentin is an anticonvulsant that was synthesized as a
structural analog to gamma-aminobutyric acid (22). Intrathe-
cal or systemic administration of gabapentin diminishes
hyperalgesia in tissue injury pain models without affecting
acute noxious stimuli threshold (23, 24). Furthermore, the
antinociceptive effect of gabapentin is more powerful after
intrathecal rather than systemic administration (25). These
findings suggest that gabapentin may alter the facilitated
state and the major site of action of gabapentin may be the
spinal cord. Although the mechanisms of action of gabapen-
tin are not clear, the relations to specific receptors (22, 23)
or substances (26), L-amino acid transporter (27), or voltage-
dependent calcium channel (28) has been proposed as the
site of action of gabapentin. It has been reported that gaba-
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Fig. 3. Isobologram for the intrathecal interaction of gabapentin
and N
6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA). Hori-
zontal and vertical bars indicate SEM. The diagonal line connect-
ing both 50% effective dose (ED50) points is the theoretical addi-
tive line. The ED50 point A is calculated from the ED50 values and
95% confidence intervals of each drug. The experimental ED50
point B lies far below the line of additivity, indicating significant
synergism.
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Fig. 4. Antagonism by 8-cyclopentyl-1,3-dipropylxanthine (DPCPX)
pretreatment. Pretreatment with DPCPX 10 μ g was performed 15
min before injection of a large dose in the gabapentin plus N
6-(2-
phenylisopropyl)-adenosine R-(-)isomer (R-PIA) group. Graphs
show the time course of the antiallodynic effect in the combina-
tion group and pretreatment groups. Data are expressed as mean
±SEM. Maximal antagonism is seen after 30 and 45 min. Aster-
isks indicate that mean percent maximal possible effect (%MPE)
of pretreatment groups for antiallodynia at that time point is sig-
nificantly less compared with the gabapentin plus R-PIA group.
*p<0.05; unpaired t-test. I.T.; intrathecal injection.
Fig. 5. Effects of intrathecal injection of gabapentin, N
6-(2-pheny-
lisopropyl)-adenosine R-(-)isomer (R-PIA), and gabapentin plus
R-PIA on rotarod performance time. Rotarod performance time
was measured before (baseline) and after drug administration.
Rotarod performance time was not reduced by administration of
gabapentin 100 μ g and R-PIA 3, 10 μ g, and gabapentin 5 μ g plus
R-PIA 0.1 μ g. Rotarod performance time was significantly dec-
reased at 20 and 60 min after the injection of gabapentin 300 μ g.
The results are expressed as the mean±SEM. *p<0.05 vs. base-
line group by repeated-measures analysis of variance and Tukey’s
method. I.T., intrathecal injection.
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pentin decreases glutamate concentrations and inhibits the
release of glutamate and glutamatergic synaptic transmis-
sion presynaptically (29). Glutamate acts on the NMDA
and non-NMDA receptor and shows the excitatory effect
(30). Further, the AMPA-evoked neuronal response is inhib-
ited by gabapentin (31).
In our experiments, the interaction between gabapentin
and R-PIA was synergistic. We suggested that the antiallo-
dynic effect found in the combination group was mediated
by the independent receptor systems at the spinal level and
there was an attenuation in dose for each drug, and we thought
it was a synergistic interaction.
Although we cannot know the exact mechanism, there
are two possible explanations for synergistic effect. First, it
could be thought of a change in agonist affinity. An increase
in slope might reflect increased efficacy. In our experiments,
the slope was increased in the combination group and was
shifted to the left in large doses, which may explain a syner-
gistic interaction. Second, we could suggest the possibility
of functional receptor interaction. It is anticipated that the
frequency of motor weakness and sedation could be also
enhanced with increase in the antiallodynic component. In
our experiments, there were no siginificant changes in motor
function and sedation by rotarod test, so it is hard to sug-
gest the functional receptor interaction. However, the fact
that the receptors for the sensory component are mainly locat-
ed in the dorsal horn of spinal cord and that there may be
an interaction of the A1 receptor with the gabapentin recep-
tor shows the possibility of a functional receptor interaction.
In animal behavioral tests, severe sedation after drug admin-
istration could decrease response to stimulations and mask
the antiallodynic effect. The effect on motor performance is
particularly crucial in studies of spinal A1 receptor agonists
because of the possible action of a large dose of R-PIA in the
motor neuron area of the spinal cord (7). Therefore, we mea-
sured rotarod performance test to examine drug-induced
adverse effects, such as sedation or locomotor dysfunction.
Experimental rats that adjusted to the rotarod did not show
significant reduction in rotarod performance test after gaba-
pentin and R-PIA were coadministered. Thus, we suggest
that the antiallodynic effect produced by gabapentin and R-
PIA was not affected by drug-induced sedation mainly because
the amounts of doses of each drug were quite small. The
difference in action site and receptor number and function
changes after nerve injury may affect the results (32). With
respect to reduced side effect and synergistic effect, a combi-
nation therapy administering a smaller dose of each drug
and a target-specific treatment using R-PIA and gabapentin
may be beneficial to the management of allodynia.
We performed an antagonistic study with pretreatment
of DPCPX in the combination subgroup to investigate the
reversal effect, and maximal antiallodynic effect was reversed.
These findings may suggest that spinal gabapentin is inde-
pendently necessary for the optimal function of R-PIA in
producing a synergistic effect. In our experiment, we chose
only the A1 antagonist DPCPX because the A1 receptor
subtype was most effective in the reversal of mechanical allo-
dynia in the nerve ligation injury model (7). Unfortunately,
we could not find exact gabapentin antagonist, so we could
not perform the antagonistic study of gabapentin. However,
with the present experiments we cannot rule out that other
mechanisms could participate in this interaction.
In conclusion, gabapentin and R-PIA produced a dose-
dependent antiallodynia without severe side effects and int-
rathecal gabapentin produced a synergistic interaction with
R-PIA in a rat model of nerve ligation injury. Thus, these
results suggest that activation of adenosine A1 receptors are
required for the synergistic interaction between gabapentin
and R-PIA in reducing mechanical allodynia.
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